MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - MeiraGTx Holdings PLC reported a quarterly loss of $0.62 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.50, marking an earnings surprise of -24.00% [1] - The company generated revenues of $0.41 million for the quarter ended September 2025, significantly missing the Zacks Consensus Estimate by 89.95%, and down from $10.91 million in the same quarter last year [2] - The stock has increased by approximately 42.2% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, MeiraGTx has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.54 on revenues of $4.55 million, and for the current fiscal year, it is -$1.11 on revenues of $41.42 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which MeiraGTx belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5] Future Outlook - The company's earnings outlook will be crucial for investors, particularly in light of management's commentary during the earnings call [4] - The estimate revisions trend for MeiraGTx was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6]